Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus—An Ongoing Need for International Consensus and Collaborations

Josef Symon S. Concha, Aikaterini Patsatsi, Ann Marshak-Rothstein, Ming lin Liu, Animesh A. Sinha, Lela A. Lee, Joseph F. Merola, Ali Jabbari, Johann E. Gudjonsson, François Chasset, Paul Jarrett, Benjamin Chong, Lisa Arkin, Anthony P. Fernandez, Marzia Caproni, Steven A. Greenberg, Hee Joo Kim, David R. Pearson, Alisa Femia, Ruth Ann VleugelsDavid Fiorentino, Manabu Fujimoto, Joerg Wenzel, Victoria P. Werth

Research output: Contribution to journalArticlepeer-review

9 Scopus citations
Original languageEnglish (US)
Pages (from-to)270-276
Number of pages7
JournalJournal of Investigative Dermatology
Volume139
Issue number2
DOIs
StatePublished - Feb 2019
Externally publishedYes

Bibliographical note

Funding Information:
AstraZeneca, Celgene, Biogen, CSL Behring, Lilly, Pfizer, Idera, Octapharma, Corbus Pharmaceuticals, Resolve, and the Lupus Foundation of America provided support for this meeting.

Funding Information:
This work was supported by the U.S. Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, and Biomedical Laboratory Research and Development) Merit Review 5 I01 BX000706-04 (primary investigator: VPW) and by the US Department of Health and Human Services and the National Institutes of Health (National Institute of Arthritis and Musculoskeletal and Skin Diseases) R21 AR066286 (primary investigator: VPW).

Funding Information:
This work was supported by the U.S. Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, and Biomedical Laboratory Research and Development) Merit Review 5 I01 BX000706-04 (primary investigator: VPW) and by the US Department of Health and Human Services and the National Institutes of Health (National Institute of Arthritis and Musculoskeletal and Skin Diseases) R21 AR066286 (primary investigator: VPW).

Funding Information:
FC serves on the advisory board for GSK and Celgene. Benjamin Chong is primary investigator for Pfizer, Biogen, and Daavlin and has received an honorarium for Celgene Corporation as a consultant. APF is principal investigator for dermatomyositis clinical trials and received research funding from Mallinckrodt and Pfizer and has participated in advisory board meetings for Celgene concerning lupus erythematosus. SAG is inventor of intellectual property related to myositis diagnostics and therapeutics, owned and managed by Brigham and Women’s hospital; received sponsored research from Pfizer; and is founder of Abcuro. JEG received research support from SunPharma, Amgen, and Pfizer and served on advisory boards for Novartis and MiRagen. Joseph Merola has been a consultant for Merck Research Laboratories; AbbVie, Eli Lilly and Company, Novartis, Janssen, UCB, Samumed, Celgene, Sanofi Regeneron, and GSK; has served on the speaker’s bureau for AbbVie; has been an investigator for Biogen, Pfizer, Sanofi Regeneron, Incyte, Aclaris, Novartis; provided financial consulting for Cowen Healthcare; and served on the editorial board for Wellspring Health, Inc. RAV is a consultant for Pfizer. Victoria Werth has provided consulting for Celgene, Medimmune, Resolve, Neovacs, Genetech, Idera, Octapharma, BSL Behring, Janssen, Lilly, Pfizer, Biogen, BMS, Gilead, Amgen, Medscape, Nektar, Incyte, EMD Sorona, and CSL Behring and has received grants from Celgene, Janssen, Pfizer, Biogen, Gilead, Corbus Pharmaceuticals, Genentech, and AstraZeneca.

Cite this